Dystrophin mutations predict cellular susceptibility to oxidative stress

Muscle and Nerve

Volumn 23, Issue 5, 2000, Pages 784-792

  Disatnik, Marie Hélène ^a,b   Chamberlain, Jeffrey S ^c   Rando, Thomas A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Neurology Service   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Dystrophin; mdx; Muscular dystrophy; Oxidative stress; Transgenic

Indexed keywords

CREATINE KINASE; DYSTROPHIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; GENE; GENE MUTATION; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CALCIMYCIN; CELLS, CULTURED; DYSTROPHIN; MICE; MICE, INBRED MDX; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUTATION; OXIDATIVE STRESS; PARAQUAT; STAUROSPORINE; VITAMIN K;

EID: 0034100628     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200005)23:5<784::AID-MUS17>3.0.CO;2-Y     Document Type: Article

References (58)

1. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet 1993;3:283-291.
2. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995;92:7162-7166.
3. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995;82:743-752.
4. Brown SC, Fassati A, Popplewell L, Page AM, Henry MD, Campbell KP, Dickson G. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycanlaminin interaction. J Cell Sci 1999;112:209-216.
5. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 1984;81:1189-1192.
6. Cavaldesi M, Macchia G, Barca S, Defilippi P, Tarone G, Petrucci TC. Association of the dystroglycan complex isolated from bovine brain synaptosomes with proteins involved in signal transduction. J Neurochem 1999;72:1648-1655.
7. Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, Padre RC, Spencer MJ, Tidball JG, Stull JT. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 1996;93:9142-9147.
8. Chao DS, Gorospe JR, Brenman JE, Rafael JA, Peters MF, Froehner SC, Hoffman EP, Chamberlain JS, Bredt DS. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 1996;184:609-618.
9. Chao DS, Silvagno F, Bredt DS. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase. J Neurochem 1998;71:784-789.
10. Cox GA, Cole NM, Matsumura K, Phelps SF, Hauschka SD, Campbell KP, Faulkner JA, Chamberlain JS. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993;364:725-729.
11. Cox GA, Sunada Y, Campbell KP, Chamberlain JS. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet 1994;8: 333-339.
12. Crosbie RH, Straub V, Yun HY, Lee JC, Rafael JA, Chamberlain JS, Dawson VL, Dawson TM, Campbell KP. Mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 1998;7:823-829.
13. Disatnik MH, Dhawan J, Yu Y, Beal MF, Whirl MM, Franco AA, Rando TA. Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. J Neurol Sci 1998;161:77-84.
14. Disatnik MH, Rando TA. Integrin-mediated muscle cell spreading: the role of protein kinase C in outside-in and inside-out signaling and evidence of integrin cross-talk. J Biol Chem 1999;274:32486-32492.
15. Engel WK. Duchenne muscular dystrophy: a histologically based ischemia hypothesis and comparison with experimental ischemia myopathy. In: Pearson CM. Mostofi FK, editors. The striated muscle. Baltimore: Williams & Wilkins; 1973. p 453-472.
16. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990;343:180-182.
17. Franco AA, Odom RS, Rando TA. Regulation of antioxidant enzyme gene expression in response to oxidative stress and during differentiation of mouse skeletal muscle. Free Radic Biol Med 1999;27:1122-1132.
18. Goldberg LR, Hausmanowa-Petrusewicz I, Fidzianska A, Duggan DJ, Steinberg LS, Hoffman EP. A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. Ann Neurol 1998; 44:971-976.
19. Greenberg DS, Sunada Y, Campbell KP, Yaffe D, Nudel U. Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice [see comments]. Nat Genet 1994;8:340-344.
20. Hack AA, Ly CT, Jiang F, Clendenin CJ, Sigrist KS, Wollmann RL, McNally EM. Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J Cell Biol 1998;142:1279-1287.
21. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
22. Hattori N, Kaido M, Nishigaki T, Inui K, Fujimura H, Nishimura T, Naka T, Hazama T. Undetectable dystrophin can still result in a relatively benign phenotype of dystrophinopathy. Neuromuscul Disord 1999;9:220-226.
23. Hauser E, Hoger H, Bittner R, Widhalm K, Herkner K, Lubec G. Oxyradical damage and mitochondrial enzyme activities in the mdx mouse. Neuropediatrics 1995;26:260-262.
24. Hayashi YK, Chou FL, Engvall E, Ogawa M, Matsuda C, Hirabayashi S, Yokochi K, Ziober BL, Kramer RH, Kaufman SJ, Ozawa E, Goto Y, Nonaka I, Tsukahara T, Wang JZ, Hoffman EP, Arahata K. Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet 1998;19:94-97.
25. Haycock JW, MacNeil S, Jones P, Harris JB, Mantle D. Oxidative damage to muscle protein in Duchenne muscular dystrophy. Neuroreport 1996;8:357-361.
26. Kachinsky AM, Froehner SC, Milgram SL. A PDZ-containing scaffold related to the dystrophin complex at the basolateral membrane of epithelial cells. J Cell Biol 1999;145:391-402.
27. Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Endo M, Hanaoka K, Nabeshima Y, Takeda S. Alphal-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 1999;274:2193-2200.
28. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994;233:346-357.
29. Malhotra SB, Hart KA, Klamut HJ, Thomas NS, Bodrug SE, Burghes AH, Bobrow M, Harper PS, Thompson MW, Ray PN. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 1988;242:755-759.
30. Mayer U, Saher G, Fassler R, Bornemann A, Echtermeyer F, von der MH, Miosge N, Poschl E, von der MK. Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat Genet 1997;17:318-323.
31. McArdle A, Edwards RH, Jackson MJ. How does dystrophin deficiency lead to muscle degeneration? - evidence from the mdx mouse. Neuromuscul Disord 1995;5:445-456.
32. Meredith JE Jr. Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-961.
33. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988;2:90-95.
34. Montanaro F, Lindenbaum M, Carbonetto S. Alpha-dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability. J Cell Biol 1999;145:1325-1340.
35. Murphy ME, Kehrer JP. Oxidative stress and muscular dystrophy. Chem Biol Interact 1989;69:101-173.
36. Ohlendieck K, Campbell KP. Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol 1991;115:1685-1694.
37. Passos-Bueno MR, Vainzof M, Marie SK, Zatz M. Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. Hum Mol Genet 1994;3:919-922.
38. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995;4:1251-1258.
39. Rafael JA, Sunada Y, Cole NM, Campbell KP, Faulkner JA, Chamberlain JS. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet 1994;3:1725-1733.
40. Ragusa RJ, Chow CK, Porter JD. Oxidative stress as a potential pathogenic mechanism in an animal model of Duchenne muscular dystrophy. Neuromuscul Disord 1997;7:379-386.
41. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994;125:1275-1287.
42. Rando TA, Crowley RS, Carlson EJ, Epstein CJ, Mohapatra PK. Overexpression of copper/zinc superoxide dismutase: a novel cause of murine muscular dystrophy. Ann Neurol 1998; 44:381-386.
43. Rando TA, Disatnik MH, Yu Y, Franco A. Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord 1998;8:14-21.
44. Rando TA, Epstein CJ. Copper/zinc superoxide dismutase: more is not necessarily better. Ann Neurol 1999;46:135-136.
45. Schwartz MA. Transmembrane signalling by integrins. Trends Cell Biol 1992;2:304-308.
46. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580.
47. Straub V, Campbell KP. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 1997;10; 168-175.
48. Taverna D, Disatnik MH, Rayburn H, Bronson RT, Yang J, Rando TA, Hynes RO. Dystrophic muscle in mice chimeric for expression of alpha5 integrin. J Cell Biol 1998;143: 849-859.
49. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 1998;95:15090-15095.
50. Tidball JG, Albrecht DE, Lokensgard BE, Spencer MJ. Apoptosis precedes necrosis of dystrophin-deficient muscle. J Cell Sci 1995;108:2197-2204.
51. Walker PM. Ischemia/reperfusion injury in skeletal muscle. Ann Vasc Surg 1991;5:399-402.
52. Wehling M, Stull JT, McCabe TJ, Tidball JG. Sparing of mdx extraocular muscles from dystrophic pathology is not attributable to normalized concentration or distribution of neuronal nitric oxide synthase. Neuromuscul Disord 1998;8:22-29.
53. Wells DJ, Wells KE, Walsh FS, Davies KE, Goldspink G, Love DR, Chan-Thomas P, Dunckley MG, Piper T, Dickson G. Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. Hum Mol Genet 1992;1:35-40.
54. Wink DA, Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 1998;25:434-456.
55. Winnard AV, Klein CJ, Coovert DD, Prior T, Papp A, Snyder P, Bulman DE, Ray PN, McAndrew P, King W. Characterization of translational frame exception patients in Duchenne/ Becker muscular dystrophy. Hum Mol Genet 1993;2:737-744.
56. Yoshida T, Pan Y, Hanada H, Iwata Y, Shigekawa M. Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J Biol Chem 1998;273: 1583-1590.
57. Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and upregulates Bcl-2 expression. Proc Natl Acad Sci U S A 1995;92: 6161-6165.
58. Zychlinsky A, Zheng LM, Liu CC, Young JD. Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 1991;146:393-400.